(Q33416223)

26 July 2017

title

Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis (English)

1 reference

chronic idiopathic myelofibrosis

26 July 2017

1 reference

1 reference

Chiara Milanesi

15

0 references

Virginia Ferretti

Virginia Ferretti

17

0 references

Lisa Pieri

Lisa Pieri

8

0 references

Daniela Pietra

Daniela Pietra

2

0 references

Vittorio Rosti

Vittorio Rosti

19

0 references

Dolors Colomer

Dolors Colomer

7

0 references

Paola Guglielmelli

Paola Guglielmelli

4

0 references

Monica Corada

0 references

Elena Fugazza

1 reference

ORCID Public Data File 2021

author name string

Elisa Rumi

1

1 reference

26 July 2017

Cristiana Pascutto

3

1 reference

26 July 2017

Alejandra Martínez-Trillos

5

1 reference

26 July 2017

Ilaria Casetti

6

1 reference

26 July 2017

Marta Pratcorona

9

1 reference

26 July 2017

Giada Rotunno

10

1 reference

26 July 2017

Emanuela Sant'Antonio

11

1 reference

26 July 2017

Marta Bellini

12

1 reference

26 July 2017

Chiara Cavalloni

13

1 reference

26 July 2017

Carmela Mannarelli

14

1 reference

26 July 2017

Emanuela Boveri

16

1 reference

26 July 2017

Cesare Astori

18

1 reference

26 July 2017

Francisco Cervantes

20

1 reference

26 July 2017

Giovanni Barosi

21

1 reference

26 July 2017

Alessandro M Vannucchi

22

1 reference

26 July 2017

Mario Cazzola

23

1 reference

26 July 2017

Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators

24

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 July 2014

1 reference

26 July 2017

1 reference

26 July 2017

volume

124

1 reference

26 July 2017

issue

7

1 reference

26 July 2017

page(s)

1062-1069

1 reference

Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes

26 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133481

Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133481

Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133481

CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133481

CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133481

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133481

Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133481

Somatic mutations of calreticulin in myeloproliferative neoplasms

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133481

The genetic basis of myelodysplasia and its clinical relevance

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133481

Clinical and biological implications of driver mutations in myelodysplastic syndromes

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133481

Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133481

JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133481

Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133481

European consensus on grading bone marrow fibrosis and assessment of cellularity

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133481

Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133481

The Analysis of Failure Times in the Presence of Competing Risks

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133481

From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133481

Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133481

Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133481

Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133481

Mutations and prognosis in primary myelofibrosis

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133481

Cardiovascular events and intensity of treatment in polycythemia vera

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133481

A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133481

Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133481

Clinical relevance of extra-hematologic comorbidity in the management of patients with myelodysplastic syndrome

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133481

Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133481

Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133481

Diagnostic and clinical relevance of the number of circulating CD34+ cells in myelofibrosis with myeloid metaplasia

31 October 2018

1 reference

12 December 2020

A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).

1 reference

12 December 2020

SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival

1 reference

12 December 2020

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

1 reference

12 December 2020

10.1182/BLOOD-2014-05-578435

Identifiers

DOI

1 reference

release_4bs3mc5gmjh2nleutlbwpbmob4

26 July 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/4bs3mc5gmjh2nleutlbwpbmob4

24 November 2022

mapped directly with Wikidata item

PMC publication ID

4133481

1 reference

26 July 2017

1 reference